)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Balaxi Pharmaceuticals
Balaxi Pharmaceuticals (BALAXI) investor relations material
Balaxi Pharmaceuticals Investor presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor presentation summary6 Aug, 2026
Business overview and strategy
Focuses on branded, IPR-driven pharmaceuticals in frontier markets, especially Latin America and Africa, with a strong presence in OTC and branded generics segments.
Operates an asset-light model, now transitioning to asset-right with its first manufacturing facility in Hyderabad for backward integration and global expansion.
Deep distribution network with 38 warehouses and on-ground fleet, supported by digital procurement and regulatory management tools.
Targets top-2 market positions in each geography, leveraging local regulatory compliance and a motivated expatriate leadership team.
Expansion underway in new Latin American markets, with 980 product registrations and over 200 more in the pipeline.
Financial performance
Q1 FY27 revenue grew 14% YoY to ₹80.68 crore, with gross profit margin up 241 bps to 46.5%.
Profit after tax for Q1 FY27 rose to ₹1.29 crore from ₹0.29 crore YoY, with EPS up 380%.
FY26 revenue declined 7.7% YoY to ₹270.17 crore, with EBITDA margin dropping to 4.2% and PAT margin to 0.5%.
Management expects further improvement as operating leverage strengthens and strategic initiatives mature.
Operations and product portfolio
Commercial production commenced at the Hyderabad facility, focusing on general oral solid dosage for Latin America and Africa.
Product mix includes branded and generic medicines, with a broad therapeutic portfolio: antibiotics, analgesics, anti-malaria, vitamins, and more.
Q1 FY27 product sales split: 54% branded, 46% generics; 60% tablets, 40% injectables/liquids.
16 new product registrations in Q1 FY27, total portfolio now at 980 registered products.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Balaxi Pharmaceuticals
- Profit declined as investment income supported results; expansion plans and fresh capital remained under consideration.BALAXI
Q4 11/12 - Lower investment-related income cut profit; a 9% dividend and rights issue were proposed.BALAXIQ4 12/13
- FY14 net profit rose to Rs1.10m as a Rs26.25m share issue was proposed.BALAXIQ4 13/14
- Investment income lifted revenue, but FY15 profit slipped and exchange listing remained unresolved.BALAXIQ4 14/15
- Revenue fell and results swung to a loss as investment activity remained the sole business mix.BALAXIQ4 15/16
- An inactive investment business posted a wider FY18 loss as its planned equity raise was withdrawn.BALAXIQ4 17/18
- Share-trading losses hit FY17 as ownership changed and diversification plans emerged.BALAXIQ4 16/17
- Seven-month trading launch erased accumulated losses and opened export and food-growth avenues.BALAXIQ4 18/19
- FY20 earnings surged as distribution expanded into new markets and sourcing channels.BALAXIQ4 19/20
- Revenue surged 407%, while working-capital growth constrained operating cash flow.BALAXIQ4 20/21
Next Balaxi Pharmaceuticals earnings date
Q2 26/2712 Nov, 2026
Balaxi Pharmaceuticals
Next Balaxi Pharmaceuticals earnings date
Q2 26/2712 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Balaxi Pharmaceuticals Limited is a pharmaceutical company engaged in the manufacturing, marketing, and distribution of branded generic formulations. The company offers a wide range of dosage forms including tablets, capsules, syrups, and injectables across various therapeutic segments such as anti-infectives, gastroenterology, and pain management. The company is headquartered in Hyderabad, India, and its shares are listed on the BSE.